Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 00534A102 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Janus Henderson Group PLC
13G/A
|
12.1% |
11/14/2025
Event 9/30/2025
|
||
| Janus Henderson Group PLC | 12.1% | |||
| Janus Henderson Biotech Innovation Master Fund Ltd | 10.3% | |||
|
Biotechnology Value Fund L P
13G/A
|
10.0% |
8/14/2026
Event 6/30/2026
|
||
| Biotechnology Value Fund L P | 5.4% | |||
| BVF I GP LLC | 5.4% | |||
| Biotechnology Value Fund II LP | 3.8% | |||
| BVF II GP LLC | 3.8% | |||
| Biotechnology Value Trading Fund OS LP | 0.6% | |||
| BVF Partners OS Ltd. | 0.6% | |||
| BVF GP Holdings LLC | 9.2% | |||
| BVF Partners L P/IL | 10.0% | |||
| BVF Inc/IL | 10.0% | |||
| Lampert Mark N | 10.0% | |||
| Adimab, LLC 13D/A | 7.3% |
12/29/2025
Event 12/23/2025
|
||
|
RA Capital Management, L.P.
13G/A
|
7.0% |
5/15/2026
Event 3/31/2026
|
||
| RA Capital Management, L.P. | 7.0% | |||
| Peter Kolchinsky | 7.0% | |||
| Rajeev Shah | 7.0% | |||
| RA Capital Healthcare Fund, L.P. | 7.0% | |||
|
Maverick Capital, Ltd.
13G/A
|
6.7% |
2/13/2026
Event 12/31/2025
|
||
| Maverick Capital, Ltd. | 6.7% | |||
| Maverick Capital Management, LLC | 6.7% | |||
| Lee S. Ainslie III | 6.7% | |||
|
Perceptive Advisors LLC
13G/A
|
6.3% |
8/14/2026
Event 6/30/2026
|
||
| Perceptive Advisors LLC | 6.3% | |||
| Joseph Edelman | 6.3% | |||
| Perceptive Life Sciences Master Fund, Ltd. | 6.3% | |||
| BlackRock, Inc. 13G | 5.5% |
7/28/2026
Event 6/30/2026
|
||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (7) | ||||
|
Mithril II LP
13D/A
|
4.8% |
11/12/2025
Event 8/22/2025
|
||
| Mithril II LP | 4.8% | |||
| Mithril II GP LP | 4.8% | |||
| Mithril II UGP LLC | 4.8% | |||
| Ajay Royan | 4.8% | |||
| Peter Thiel | 4.8% | |||
|
FMR LLC
13G/A
|
4.8% |
2/12/2025
Event 12/31/2024
|
||
| FMR LLC | 4.8% | |||
| Abigail P. Johnson | 4.8% | |||
|
M28 Capital Management LP
13D/A
|
4.6% |
8/26/2025
Event 8/22/2025
|
||
| M28 Capital Management LP | 4.4% | |||
| Marc Elia | 4.6% | |||
|
Polaris Venture Partners V, L.P.
13D/A
|
3.0% |
11/7/2025
Event 8/22/2025
|
||
| Polaris Venture Partners V, L.P. | 1.3% | |||
| Polaris Venture Partners Entrepreneurs' Fund V, L.P. | 0% | |||
| Polaris Venture Partners Founders' Fund V, L.P. | 0% | |||
| Polaris Venture Partners Special Founders' Fund V, L.P. | 0% | |||
| Polaris Venture Management Co. V, L.L.C. | 1.4% | |||
| Polaris Partners IX, L.P. | 1.3% | |||
| Polaris Partners GP IX, L.L.C. | 1.3% | |||
| Polaris Healthcare Technology Opportunities Fund, L.P. | 0.2% | |||
| Polaris Healthcare Technology Opportunities Fund GP, L.L.C. | 0.2% | |||
| Terrance McGuire | 3.0% | |||
| Jonathan Flint | 1.4% | |||
|
Soleus Private Equity Fund III, L.P.
13G/A
|
2.8% |
2/12/2026
Event 12/31/2025
|
||
| Soleus Private Equity Fund III, L.P. | 0.6% | |||
| Soleus Private Equity GP III, LLC | 0.6% | |||
| Soleus PE GP III, LLC | 0.6% | |||
| Soleus Capital Master Fund, L.P. | 2.2% | |||
| Soleus Capital, LLC | 2.2% | |||
| Soleus Capital Group, LLC | 2.2% | |||
| Soleus Capital Management, L.P. | 2.8% | |||
| Soleus GP, LLC | 2.8% | |||
| Guy Levy | 2.8% | |||
|
Point72 Asset Management, L.P.
13G/A
|
0% |
5/15/2026
Event 3/31/2026
|
||
| Point72 Asset Management, L.P. | 0% | |||
| Point72 Capital Advisors, Inc. | 0% | |||
| Steven A. Cohen | 0% | |||
|
Deep Track Capital, LP
13G/A
|
0% |
11/14/2025
Event 9/30/2025
|
||
| Deep Track Capital, LP | 0% | |||
| Deep Track Biotechnology Master Fund, Ltd. | 0% | |||
| David Kroin | 0% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 2 | 2.90 k | $2.53 k |
| 2026 Q2 | 133 | 233 M | $206 M |
| 2026 Q1 | 147 | 228 M | $297 M |
| 2025 Q4 | 121 | 240 M | $594 M |
| 2025 Q3 | 84 | 149 M | $164 M |
| 2025 Q2 | 71 | 60.5 M | $43.2 M |
| 2025 Q1 | 84 | 70.4 M | $42.6 M |
| 2024 Q4 | 81 | 76.9 M | $34.1 M |
| 2024 Q3 | 81 | 71.6 M | $73.0 M |
| 2024 Q2 | 88 | 76.3 M | $83.9 M |
| 2024 Q1 | 96 | 72.5 M | $322 M |
| 2023 Q4 | 65 | 55.9 M | $220 M |
| 2023 Q3 | 59 | 53.5 M | $90.9 M |
| 2023 Q2 | 60 | 55.9 M | $58.7 M |
| 2023 Q1 | 75 | 60.0 M | $71.9 M |
| 2022 Q4 | 88 | 60.8 M | $91.2 M |
| 2022 Q3 | 83 | 62.0 M | $194 M |
| 2022 Q2 | 82 | 60.7 M | $207 M |
| 2022 Q1 | 84 | 59.3 M | $274 M |
| 2021 Q4 | 88 | 60.0 M | $432 M |
| 2021 Q3 | 68 | 52.2 M | $2.16 B |